Archive · 25 Sep 2025
Natco Pharma Board Approves Demerger of Agro Business
Natco Pharma is splitting into two companies.
One will focus on its main drug business, and the other on its agro business.
The company's board approved this plan to help the drug business grow faster and be more efficient.
They hope this split will lead to better performance for each part of the business.
Natco Pharma may keep a small part of the agro company to help with things like research and development.
Natco Pharma made about Rs 4,784 crore in revenue in the fiscal year 2025 and has around 5,000 employees.
Natco Pharma's board approved the demerger of its agro business.
The demerger aims to unlock value and enhance the core pharmaceutical business growth.
The demerger is expected to provide operational flexibility and dedicated management.
Natco Pharma may retain a minority stake in the new agro company.
The company reported Rs 4,784 crore in revenue in FY25.
- Who
- Natco Pharma
- What
- The board approved the demerger of the agro business from the core pharmaceutical business.
- When
- Thursday
- Where
- N/A
- Why
- To unlock value in the core pharmaceuticals business, enhance growth, and provide operational flexibility.
- Company
- Natco Pharma
- Action
- Demerger of agro business
- Revenue FY25
- Rs 4,784 crore
- PAT FY25
- Rs 1,883 crore
- Employees
- About 5,000 globally
- Scientists
- 500